Canadian journal of anaesthesia = Journal canadien d'anesthésie
-
Randomized Controlled Trial Clinical Trial
Neostigmine, pyridostigmine and edrophonium as antagonists of deep pancuronium blockade.
To compare the ability of equipotent doses of neostigmine, pyridostigmine and edrophonium to antagonize intense pancuronium neuromuscular blockade, one hundred and twenty ASA physical status I or II patients scheduled for elective surgery received 0.06 mg.kg-1 pancuronium during a thiopentone nitrous oxide-enflurane anaesthetic. Train-of-four stimulation was applied every 12 s and the force of contraction of the adductor pollicis muscle was recorded. In the first 60 patients, spontaneous recovery was allowed until ten per cent of initial first twitch height. ⋯ These doses were given by random allocation to the next 60 patients, but at one per cent spontaneous recovery. Neostigmine, 0.04 mg.kg-1, produced a T1 of 73 +/- 4 per cent (mean +/- SEM), and a train-of-four ratio (TOF) of 39 +/- 3 per cent. This was significantly greater than with pyridostigmine, 0.2 mg.kg-1 (T1 = 50 +/- 6 per cent; TOF = 25 +/- 3 per cent), and edrophonium, 0.54 mg.kg-1 (T1 = 54 +/- 3 per cent; TOF = 17 +/- 2 per cent).(ABSTRACT TRUNCATED AT 250 WORDS)
-
Randomized Controlled Trial Clinical Trial
Cardiovascular effects of non-depolarizing neuromuscular blockers in patients with aortic valve disease.
To compare haemodynamic responses associated with equipotent doses of neuromuscular blockers and high-dose fentanyl (50 micrograms.kg-1), 40 patients with aortic valve stenosis (AS) and 20 patients with aortic insufficiency (AI) were randomized to four study groups to receive the following: (1) pancuronium 0.12 mg.kg-1, (2) vecuronium 0.12 mg.kg-1, (3) atracurium 0.4 mg.kg-1, or (4) pancuronium-metocurine mixture (0.4 mg + 1.6 mg/ml): 1 ml/10 kg). Neuromuscular blockers were injected at the same time with the fentanyl; haemodynamics were recorded with the patients awake (baseline), at two minutes post-induction, and at two and five minutes after intubation. In patients with AS, pancuronium increased heart rate more than vecuronium or atracurium; heart rates were also higher with the pancuronium-metocurine mixture than with vecuronium. ⋯ Atracurium caused unexplained elevations in diastolic and mean arterial pressures which were significant when compared to vecuronium (p less than 0.01). These results in increases in PCWP; mean PA pressures and CVP were also increased. These effects of atracurium inpatients with Al need further evaluation.